[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453181":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":27,"responsibleParty":40,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DAOIB+Omega-3","EXPERIMENTAL",null,[13],"Drug: DAOIB+Omega-3",{"label":15,"type":16,"description":11,"interventionNames":17},"DAOIB+Placebo","PLACEBO_COMPARATOR",[18],"Drug: DAOIB+Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Placebo",[15],[28],{"facility":29,"status":11,"city":30,"state":11,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":11},"Kaohsiung Chang Gung Memorial Hospital","Kaohsiung City","886","Taiwan","TW",{"type":35,"coordinates":36},"Point",[37,38],120.31333,22.61626,{"lat":38,"lon":37},{"type":41,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100453181","phase-2-nmda-enhancement-combined-with-omega-3-for-early-dementia-100453181",false,"NCT05181189","NMDA Enhancement Combined With Omega-3 for Early Dementia","NMDA Enhancement Combined With Omega-3 Fatty Acids for the Treatment of Early Dementia","Inclusion Criteria:\n\n* Clinical diagnosis of Alzheimer's disease or mild cognitive impairment\n* MMSE between 10-26\n* CDR 1 or 0.5\n\nExclusion Criteria:\n\n* Hachinski Ischemic Score \\> 4\n* Substance abuse\u002Fdependence\n* Parkinson disease, epilepsy, dementia with psychotic features\n* Major depressive disorder\n* Major physical illnesses\n* memantine or special omega-3 fatty acids therapy within 3 months before enrollment\n* Severe visual or hearing impairment","ALL","50 Years","100 Years",{"count":53,"type":54},140,"ESTIMATED","INTERVENTIONAL",[57],"PHASE2","In this 4-year proposed project, we will enroll 140 patients with aMCI or mild AD into a 24-week randomized, double-blind, placebo-controlled drug trial. All patients will be allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a double-blind manner: \\[1\\] DAOIB + omega-3; \\[2\\] DAOIB + placebo. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB combined with omega-3 will yield better efficacy than placebo in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.",[60,61],"Omega 3 Fatty Acids","Dementia","NOT_YET_RECRUITING","2026-03-18",{"date":65,"type":66},"2026-03-20","ACTUAL",{"date":68,"type":54},"2026-08",{"date":70,"type":54},"2028-03",{"name":5,"class":6},1]